Insider buying last 90 days
No open-market insider purchases were filed for OSCR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Oscar Health moved this week on third-quarter results, as the company reported a profit of $0.49 per share against an expected loss of $0.14, beating estimates, with revenue projected to surge 58.1% to $4.7 billion for the quarter. The company raised its full-year 2026 operating earnings outlook for the third time, citing higher membership, premium rates, and a $250 million benefit from updated risk-adjustment data. Despite the beat and raised guidance, shares reacted with an 11.8% average absolute move historically, and the last reaction to earnings was -12.9%.
The stock closed at $32.14, up 4.9%, sitting above both its 50-day average of $31.87 and 200-day average of $24.09, with the 50-day above the 200-day. The GekkoIndex reads 58.2, placing OSCR in the Neutral zone, down 2.3 over five days. Price sits 4.5% below Gekko Fair Value of $33.66. One-year return stands at 94.1%, while the one-month return is -3.7%.
The next earnings date falls on 9 February 2027, outside a typical 20-trading-day hold. Over the last 30 days, 2 unusual options signals appeared, with call premium of $662,732 against put premium of $33,579. Analyst consensus across 9 firms shows 3 buy, 5 hold, and 1 sell ratings, with a consensus target of $36.40. Seasonality over the next 20 trading days has averaged -5.6% across 5 years, rising in 2 of them, a pattern worth noting alongside the current setup.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Oscar Health scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $31.05 sits between the 50-day ($32.00) and 200-day ($24.43) averages, or the averages disagree.
See the chart60.3, Accumulation
Reading 60.3 is in the Accumulation zone.
See the GekkoIndex8.7% below
Price is 8.7% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 86 days
Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.
See earnings−2.3% on average
From this point in the calendar, the next 20 trading days averaged −2.3% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Oscar Health closed at $31.05 on Nov 13, 2026, +105.6% over the past year, inside a 52-week range of $10.69 to $38.50.
Use the left and right arrow keys to read daily values.
Put OSCR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Oscar Health provides health insurance to people across the United States, with plans built for individuals and families, small businesses, and those eligible for Medicare Advantage. The company has become known for pairing coverage with its own technology platform, called +Oscar, which connects doctors, insurers, and the members or patients they serve.
Beyond selling insurance plans directly to consumers and businesses, Oscar Health also offers reinsurance arrangements as part of its business. The +Oscar platform itself is positioned as a tool that other healthcare providers and payers can use to manage engagement with their own patient and member bases.
The company was founded in 2012 under the name Mulberry Health Inc. before adopting its current name, Oscar Health, Inc., in January 2021. It is headquartered in New York, New York, and its shares are listed on the NYSE under the ticker OSCR.
Oscar Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.3, in the Accumulation zone, up 1.5 points over five sessions.
Up 1.5 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 22 | +9.6% | +16.9% | ||
| Accumulation (current zone) | 241 | +1.4% | +7.2% | ||
| Neutral | 357 | +0.6% | +2.8% | ||
| Distribution | 77 | +1.4% | +0.1% | ||
| Selling | 5 | Too few readings yet | |||
Average OSCR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Oscar Health trades 8.7% below Gekko Fair Value of $34.00, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Oscar Health shares are worth, recalculated every trading day.
$34.00
Gekko Fair Value, Nov 14, 2026
8.7% Undervalued
At the end of Aug 2026 the price was 1.3% below the estimate.
No open-market insider purchases were filed for Oscar Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for OSCR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in OSCR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Oscar Health has been buying back its own shares.
From company filings.
1signal, 90% of the flagged premium in calls.
Latest: Bullish flow on Nov 5, $344K in unusual premium.
1of the funds Gekko tracks holds OSCR.
Oscar Health reports on Feb 9, 2027, before the open (86 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 9, 2027
Expected before the open, 86 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 5, 2026 | $0.49 est −$0.14 | $5.14B est $4.69B | −12.9% |
| Aug 6, 2026 | $1.10 est $0.43 | $4.79B est $4.73B | −7.3% |
| May 6, 2026 | $2.07 est $1.10 | $4.58B est $4.90B | +16.3% |
| Feb 10, 2026 | −$1.24 est −$0.92 | $2.75B est $3.12B | +7.4% |
| Nov 6, 2025 | −$0.53 est −$0.55 | $2.99B est $3.05B | +4.1% |
| Aug 6, 2025 | −$0.89 est −$0.90 | $2.86B est $3.07B | +9.7% |
| May 7, 2025 | $0.92 est $0.83 | $3.05B est $2.78B | +30.5% |
| Feb 4, 2025 | −$0.62 est −$0.58 | $2.39B est $2.83B | −6.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Oscar Health is $37.00, +19.2% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 6 | UBS | $38 | +22.4% |
| Nov 6 | Piper Sandler | $45 | +44.9% |
| Nov 6 | Barclays | $49 | +57.8% |
| Oct 12 | UBS | $36 | +15.9% |
| Sep 23 | Piper Sandler | $48 | +54.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Oscar Health averaged −2.3% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.8% | 3 of 5 |
| Next 10 trading days | +7.1% | 3 of 5 |
| Next 15 trading days | +6.8% | 3 of 5 |
| Next 20 trading days | −2.3% | 3 of 5 |
| Next 30 trading days | −5.0% | 3 of 5 |
For scale, OSCR’s typical 20-trading-day move in either direction is about 15.8%.
Oscar Health’s market cap is $8.05B, with a P/E ratio of 14.2 and revenue of $17.47B over the last twelve months.
4 headlines about Oscar Health from the past week, newest first, each linking to the publisher.
Oscar Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| UNHUnitedHealth | Neutral | 9.7% above |
| ELVElevance Health | Neutral | 31.3% below |
| CICigna | Neutral | 35.4% below |
| HUMHumana | Neutral | 16.1% below |
| CNCCentene | Neutral | 19.3% below |
| MOHMolina Healthcare | Neutral | 38.6% below |
A peer links to its own page where one exists.
Oscar Health’s market cap is $8.05B at the Nov 13, 2026 close of $31.05, with 275.5M shares outstanding. The shares trade on a P/E ratio of 14.2.
The consensus analyst 12-month price target for Oscar Health is $37.00, +19.2% from the last close. Of the 9 firms that rated the stock in the last 90 days, 3 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Oscar Health is undervalued: the Nov 13, 2026 close of $31.05 is 8.7% below Gekko Fair Value of $34.00. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Oscar Health is expected to report on Feb 9, 2027, before the market opens (86 days away). Analysts expect earnings of −$1.08 per share on revenue of $4.48B. Oscar Health beat the earnings estimate in 6 of its last 8 reports, moving 11.8% on average across the report.
Oscar Health’s 52-week high is $38.50 and its 52-week low is $10.69; it closed at $31.05 on Nov 13, 2026, +105.6% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Oscar Health over the last 30 days, with $311K of flagged premium in calls and $34K in puts. The latest, bullish flow, was on Nov 5, 2026 with $344K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.